Prurigo nodularis (PN) is a rare skin condition. It causes a rash and lumps to form on your skin, which may be severely itchy. Treatment involves relieving the itching. Share on Pinterest Prurigo ...

The first and only treatment for the disabling skin condition prurigo nodularis has been approved by the Food and Drug Administration in a development a D.C. dermatologist calls “huge.” Prurigo ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA has ...

Please provide your email address to receive an email when new articles are posted on . The submission of nemolizumab for the treatment of prurigo nodularis was supported by data from the OLYMPIA ...

ZUG, Switzerland--(BUSINESS WIRE)--Galderma today announced that the New England Journal of Medicine has published full results from the phase III OLYMPIA 2 trial evaluating the efficacy and safety of ...

Please provide your email address to receive an email when new articles are posted on . By week 100, 90% of participants achieved a 4-point or higher improvement in itch and 70% experienced an ...

ORLANDO -- More than 40% of patients with longstanding prurigo nodularis (PN) had significant improvement within 3 months of starting topical ruxolitinib (Opzelura), according to a study reported here ...

Galderma has reported new interim analysis data from the OLYMPIA long-term extension trial of monoclonal antibody Nemluvio for the treatment of moderate-to-severe prurigo nodularis (PN), a chronic ...

Galderma has received filing acceptances for nemolizumab for the treatment of patients with prurigo nodularis and for adolescents and adults with moderate-to-severe atopic dermatitis in Australia, ...

Pruritic urticarial papules and plaques of pregnancy (PUPPP) are among the most common pruritic dermatoses observed in pregnant women. PUPPP appears most frequently in the third trimester, in ...